Pfizer Develops Long-Acting GLP-1 Drug to Challenge Market
Pfizer is developing a long-acting GLP-1 drug that could compete directly with established medications like Mounjaro and Zepbound when it reaches the Canadian market.
New Competition Emerges
The pharmaceutical giant's entry into the GLP-1 space represents a significant development for the Canadian market, where generic competition for semaglutide-based drugs like Ozempic and Wegovy is already expected to arrive by mid-2026.
Pfizer's long-acting formulation could offer dosing advantages over current options, though specific details about the drug's mechanism and clinical trial timeline have not been disclosed by Health Canada.
Market Impact Considerations
The potential addition of Pfizer's drug to the Canadian market comes at a time when Eli Lilly has already reduced prices for tirzepatide-based medications by 20% or more, effective December 29, 2025. This pricing pressure reflects increasing competition in the GLP-1 category.
Current Canadian pricing for established GLP-1 medications remains substantial:
Regulatory Pathway in Canada
For Pfizer's long-acting GLP-1 drug to reach Canadian patients, the company must complete clinical trials and submit a New Drug Submission to Health Canada. The regulatory agency typically requires 300 days to review new drug applications, though priority review can reduce this timeline.
Health Canada has not announced any formal submission from Pfizer for a long-acting GLP-1 medication. The agency's public drug review database currently shows ongoing reviews for nine generic semaglutide applications, which can be tracked through our generic semaglutide tracker.
Coverage Implications
Provincial drug plans and private insurers will need to evaluate coverage decisions for new GLP-1 medications as they receive Health Canada approval. Current coverage varies significantly across provinces, with some requiring prior authorization or step therapy protocols.
Patients can check their current coverage options through our insurance coverage checker, which includes information about provincial and private plan benefits for approved GLP-1 medications.
Competitive Landscape
Pfizer's potential entry adds another layer to Canada's evolving GLP-1 market. The company would compete against:
- Novo Nordisk: Semaglutide products facing generic competition in 2026
- Eli Lilly: Tirzepatide medications with recent price reductions
- Generic manufacturers: Nine companies pursuing semaglutide biosimilars
- Other innovators: Companies developing next-generation GLP-1 therapies
Market Timeline
The timeline for Pfizer's long-acting GLP-1 drug remains unclear, as clinical development and regulatory review could take several years. Meanwhile, Canadian patients can expect generic semaglutide options by summer 2026, with potential pricing reductions of 35-50% compared to brand-name products.
Additional questions about GLP-1 medications and market developments can be found in our comprehensive FAQ section.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
